Johnson & Johnson
JNJJohnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey. The company is ranked No. 42 on the 2026 Fortune 500 list of the largest United States corporations. In 2026, the company was ranked 43rd in the Forbes Global 2000. Along with Microsoft, Johnson & Johnson is one of only two U.S.-based companies that has a prime credit rating of AAA from S&P Global.
Drugs in Pipeline
265
Phase 3 Programs
177
Upcoming Catalysts
9
Next Catalyst
Oct 13, 2026
11dMarket Overview
Stock performance and key metrics
9 upcoming, 1 past
JNJ Earnings Report
EPS Est: $2.90 | FQ end Sep/2026 | Call: bmo
8 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How JNJ's past catalysts played out
galantamine ER
Alzheimer's Disease
Canagliflozin 300 mg
Diabetes Mellitus, Type 2
CONCERTA (OROS methylphenidate hydrochloride)
Attention Deficit Disorder With Hyperactivity
OROS hydromorphone HCl
Pain
Peginterferon-alpha (PegIFNα-2a)
Hepatitis C, Chronic
Decitabine 20 mg/m^2
Leukemia, Myeloid, Acute
MVA-BN-Filo
Hemorrhagic Fever, Ebola
Genetic: AAV5-hRKp.RPGR Intermediate Dose
X-Linked Retinitis Pigmentosa
Ad26.Mos4.HIV
Healthy
Icotrokinra
Crohn Disease
Remifentanil
Anesthesia
Pegylated interferon alfa-2a
Chronic Hepatitis C Virus (HCV) Infection
Sirukumab 50 mg
Depressive Disorder, Major
Guselkumab dose 1
Hidradenitis Suppurativa
Aticaprant
Depressive Disorder, Major
Milvexian
Acute Coronary Syndrome
Fentanyl 1-day transdermal patch (Titration Phase)
Pain
ER OROS paliperidone
Schizophrenia
Efgartigimod
Myasthenia Gravis
Erdafitinib
Advanced Solid Tumor
rivaroxaban 15 mg
Atrial Fibrillation
Group 2 ustekinumab 130 mg
Crohn's Disease
5-Flurouracil
Squamous Cell Carcinoma of Head and Neck
CNTO 1959 50 mg
Psoriasis
ExPEC9V
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
NUCYNTA
Pain
Paliperidone palmitate (R092670)
Schizophrenia
paliperidone palmitate injection
Schizophrenia
TAR-210
Non-Muscle Invasive Bladder Neoplasms
Vinflunine
Urothelial Cancer
Guselkumab Dose 2
Colitis, Ulcerative
PP3M 175 mg eq.
Schizophrenia
Ustekinumab IV
Colitis, Ulcerative
DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC
HIV-1
Canagliflozin 100 mg
Diabetes Mellitus, Type 2
Ad26.ZEBOV
Ebola Virus Disease
Bendamustine hydrochloride
Chronic Lymphocytic Leukemia
R331333 (referred to as JNS024 ER or CG5503)
Pain
Genetic: AAV5-hRKp.RPGR
X-Linked Retinitis Pigmentosa
Efavirenz
Human Immunodeficiency Virus-type 1 Infection
Pegylated interferon alfa-2a (PegIFNα-2a)
Hepatitis C, Chronic
Golimumab
Arthritis, Juvenile
Guselkumab 100 mg
Psoriasis
Risankizumab
Crohn Disease
Nipocalimab
Arthritis, Rheumatoid
Telaprevir
Hepatitis C, Chronic
Pegylated interferon alpha-2a
Hepatitis C Virus Genotype-1
ustekinumab 45 mg
Arthritis, Psoriatic
Durogesic® (fentanyl transdermal drug delivery system)
Chronic Pain
Paliperidone ER OROS®
Schizophrenia
Canagliflozin
Diabetes Mellitus, Type 2
Abiraterone acetate
Prostate Neoplasms
Ad26.ZEBOV 5*10^10 viral particles (vp)
Healthy
Intravenous immunoglobulins (IVIG)
Thrombocytopenia, Neonatal Alloimmune
methylphenidate
Depressive Disorder, Major
Sirukumab
Arthritis, Rheumatoid
Daratumumab IV
Multiple Myeloma
Paliperidone extended release (ER)
Schizophrenia
Ad26.RSV.PreF-based Vaccine
Respiratory Syncytial Virus Prevention
Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF
Respiratory Syncytial Viruses
D/C/F/TAF
Human Immunodeficiency Virus Type 1
Nesiritide
Heart Decompensation
Fumaric Acid Esters
Psoriasis
Temsirolimus
Mantle Cell Lymphoma
Sofosbuvir
Chronic Hepatitis C
Epo-alpha
Resuscitation
Tapentadol (CG5503) Extended Release (ER)
Pain
Rivaroxaban (Xarelto, BAY59-7939)
Venous Thromboembolism
Morphine
Hysterectomy
oxycodone
Osteoarthritis, Knee
Risperidone, long-acting injectable
Schizophrenia
risperidone; quetiapine
Bipolar Disorder
topiramate, propranolol
Migraine
Enoxaparin
Venous Thromboembolism
CG5503 IR
Bunionectomy
Acetaminophen
Post Operative Analgesia
oxycodone CR
Joint Diseases
tramadol, acetaminophen
Diabetic Neuropathies
risperidone oral tablets
Anxiety Disorders
Risperidone long-acting injectable
Schizophrenia
Tapentadol ER (100 to 250 mg twice daily)
Pain
Cyclophosphamide 750 mg/m^2
Mantle Cell Lymphoma
recombinant human erythropoietin alfa
Infarction, Middle Cerebral Artery
Micronized 17B-estradiol
Atherosclerosis
levofloxacin; amoxicillin/clavulanate
Otitis Media
VELCADE Administered by subcutaneous injection
Multiple Myeloma
Risperidone, oral tablets
Bipolar Disorders
levofloxacin, azithromycin, amoxicillin/clavulanate
Bronchitis
Conventional Antiarrhythmic Drug Therapy
Atrial Fibrillation
Test acetaminophen
Post-operative Dental Pain
CG 5503;tapentadol
Osteoarthritis
tapentadol (CG5503) ER
Low Back Pain
levofloxacin
Pneumonia
Rivaroxaban
Atrial Fibrillation
tapentadol (CG5503) Immediate Release IR
Low Back Pain
Acetaminophen/Naproxen Sodium Fixed Combination
Pain
Paliperidone extended-release
Bipolar Disorder
Risperdal Consta
Bipolar Disorder
Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)
Multiple Myeloma
paliperidone ER Oros
Schizophrenia
Gemcitabine with R115777
Pancreatic Neoplasms
Mebendazole
Healthy Volunteers
Dapoxetine
Erectile Dysfunction
F# 13418-148 Eye Drops
Ophthalmic Solutions
Rivaroxaban 2.5 mg
Acute Coronary Syndrome
Paliperidone ER
Schizophrenia
topiramate
Essential Tremor
doripenem
Pneumonia
norelgestromin + ethinyl estradiol
Contraception
Rabeprazole sodium 5 mg
Gastroesophageal Reflux
Tapentadol extended release (ER)
Diabetic Peripheral Neuropathy
Thalidomide
Multiple Myeloma
CG5503 IR;tapentadol
Arthralgia
Topiramate; Carbamazepine; Valproate
Epilepsy
levofloxacin; imipenem/cilastitin
Nosocomial Pneumonia
Pancrease MT 10.5, or MT 21
Exocrine Pancreatic Insufficiency
Colloidal Oatmeal Cream
Eczema
ivermectin
Lice Infestations
Paliperidone palmitate 25 mg eq.
Schizophrenia
JNJ-90301900 (NBTXR3)
Locally Advanced Head and Neck Squamous Cell Carcinoma
norelgestromin + ethinyl estradiol; mercilon
Contraception
Extended-release galantamine hydrobromide
Schizophrenia
Test naproxen sodium tablet
Post-operative Dental Pain
galantamine
Alzheimer's Disease
5% Minoxidil Topical Foam
Androgenetic Alopecia
Imonogas
Functional Dyspepsia
rabeprazole
Gastroesophageal Reflux Disease (GERD)
galantamine hydrobromide
Alzheimer Disease
Hydromorphone HCl
Pain
topiramate, phenytoin
Epilepsy
Paliperidone palmitate
Schizophrenia
norelgestromin + ethinyl estradiol; triphasil.
Contraception
doripenum
Urinary Tract Infections
acetaminophen extended release
Osteoarthritis
CG5503
Diabetic Neuropathy
Duragesic® (fentanyl) Therapeutic Transdermal System (TTS)
Chronic Pain
CG5503 IR; tapentadol
Osteoarthritis
5% Minoxidil
Alopecia
naproxen
Osteoarthritis, Hip
minoxidil
Androgenetic Alopecia
PDE5I (phosphodiesterase-5 inhibitor)
Erectile Dysfunction
Extended Release OROS® Paliperidone
Schizophrenia
acetaminophen Tablet
Post Operative Dental Pain
Paliperidone
Schizophrenia
Tipifarnib;Zarnestra; R115777
Acute Myeloid Leukemia
Epoetin alfa 3 times weekly /once weekly
Anemia
epoetin alfa
Chronic Kidney Disease
Prucalopride
Constipation
Tapentadol Extended Release
Tumor
Ibrutinib
Leukemia, Lymphocytic, Chronic, B-Cell
TAR-200
Non-Muscle Invasive Bladder Neoplasms
Levetiracetam
Epilepsy
Cilta-cel
Multiple Myeloma
Talquetamab
Multiple Myeloma
TMC435
Hepatitis C
JNJ-77242113
Plaque Psoriasis
Simeprevir
Hepatitis C Virus Infection
Fentanyl
Postherpetic Neuralgia
No treatment
Hepatitis C
JNJ-63723283
Multiple Myeloma
Guselkumab
Psoriasis
Daratumumab
Multiple Myeloma
Fulranumab 1 mg
Osteoarthritis
Ad26.COV2.S
Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol
Macitentan
Pulmonary Arterial Hypertension
Rilpivirine
HIV-1
Amivantamab
Carcinoma, Non-Small-Cell Lung
Sirukumab 100 mg
Arthritis, Rheumatoid
Seltorexant
Depressive Disorder, Major
Ustekinumab
Crohn Disease
Teclistamab
Multiple Myeloma
Ustekinumab 90 mg SC q8w
Crohn's Disease
Group 1: Epoetin alfa
Myelodysplastic Syndromes
Lazertinib
Carcinoma, Non-Small-Cell Lung
PP6M
Schizophrenia
Etravirine
HIV Infections
Tapentadol (CG5503)
Arthralgia
R228060
Major Depressive Disorder
Daratumumab 16 mg/kg (Part 1)
Multiple Myeloma
Capmatinib
Carcinoma, Non-Small-Cell Lung
JNJ-40411813
Major Depressive Disorder
JNJ-90301900
Carcinoma, Non-Small-Cell Lung
Experimental Product 1% Colloidal Oatmeal Balm
Atopic Dermatitis
VELCADE (bortezomib)
Multiple Myeloma
JNJ16269110
Diabetes Mellitus, Type 2
JNJ-40346527
Arthritis, Rheumatoid
ibuprofen; pseudoephedrine HCl
Enuresis
JNJ-64304500
Crohn Disease
Abiraterone
Prostate Cancer
NNC 0142-0000-0002
Inflammation
Cetrelimab
Urinary Bladder Neoplasms
Canagliflozin 50 mg
Diabetes Mellitus, Type 2
Amivantamab IV
Advanced or Metastatic Colorectal Cancer
Glucocorticoids
Myositis
tapentadol HCl
Pain
JNJ-73763989
Hepatitis B, Chronic
JNJ-39393406
Depression
JNJ-37822681
Schizophrenia
CNTO 2476 3.0 x 10^5 cells
Visual Acuity
Alimta
Non-Small Cell Lung Cancer
NNC0142-0002
Inflammation
RSV Vaccine
Healthy
R092670
Schizophrenia
Ad26.ZEBOV vaccine
Ebola Virus Disease
VELCADE
Diffuse Large B-Cell Lymphoma
Tapentadol
Pain
JNJ-41443532
Diabetes Mellitus, Type 2
Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)
Multiple Myeloma
JNJ-39588146 5 ng/kg/min
Heart Failure
tipifarnib (R115777)
Leukemia, Nonlymphocytic, Acute
JNJ39758979
Asthma
cholecalciferol
Prostate Cancer
Nesiritide (1+0.01)
Heart Failure, Congestive
R115777
Glioblastoma Multiforme
Imipenem/cilastatin
Pneumonia, Ventilator-Associated
JNJ-31001074
Attention Deficit Hyperactivity Disorder
MVA-Mosaic
Human Immunodeficiency Virus
Apalutamide
Salivary Gland Neoplasms
VX-787 300 mg
Influenza A
JNJ 40929837
Asthma
JNJ-53718678
Respiratory Syncytial Virus Infections
R209130
Schizophrenia
Daratumumab Injection
Plasma Cell Disorder
JNJ-42165279
Depressive Disorder
Olomorasib
Carcinoma, Non-Small-Cell Lung
R256918
Obesity
Ad26.RSV.preF
Respiratory Syncytial Virus
ZARNESTRA, tipifarnib, R115777
Acute Myeloid Leukemia
Siltuximab
Multicentric Castleman's Disease
Antipsychotic medication
Schizophrenia
JNJ-17166864
Allergic Rhinitis
Acetaminophen (ACE) (1000 mg)
Dental Pain
T2-18C3 therapeutic antibody
Type 2 Diabetes
Ad26.Mos.HIV
Healthy
bortezomib, dexamethasone, and thalidomide
Multiple Myeloma
JNJ-81201887
Geographic Atrophy
Oral Dexamethasone
Multiple Myeloma
PROCRIT (Epoetin alfa)
Anemia
Erdafitinib Intravesical Delivery System
Non-Muscle Invasive Bladder Neoplasms
JNJ-42847922
Depressive Disorder, Major
Acetaminophen/naproxen sodium Dose A
Pain
Standard-of-care treatment
Systemic Lupus Erythematosus
Atazanavir (ATV) 300 mg
HIV Infections
Blink® Tears eye drops in a multidose bottle
Visual Acuity
Ad26.RSV.preF (1*10^11 vp)
Respiratory Syncytial Viruses
ExPEC4V (4 : 4 : 4 : 4)
Healthy
TMC207 (bedaquiline)
Tuberculosis, Multidrug-Resistant
440 mg naproxen sodium with 1000 mg acetaminophen
Pain
JNJ-26489112
Photosensitive Epilepsy
Atomoxetine 80 mg/d
Attention Deficit Hyperactivity Disorder
ET743
Breast Neoplasms
Investigational Lubricating Eye Drop in a Novelia® bottle
Dry Eye
JNJ-39220675
Allergic Rhinitis
Escitalopram
Major Depressive Disorder
Yondelis
Liposarcoma
sIPV
Healthy
JNJ-63623872
Influenza A Virus
CNTO 1959
Palmoplantaris Pustulosis
AL-335
Hepatitis C, Chronic
JNJ 49095397
Chronic Obstructive Pulmonary Disease
JNJ-64565111 Dose Level 1
Obesity and Diabetes Mellitus, Type 2
Ketoconazole
Neoplasm Metastases
Canagliflozin (JNJ-28431754)
Diabetes Mellitus, Type II
RWJ-445380 100 mg
Rheumatoid Arthritis
Fluarix
Healthy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
galantamine ER | Phase 3 | Alzheimer's Disease | - | - |
Canagliflozin 300 mg | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
CONCERTA (OROS methylphenidate hydrochloride) | Phase 3 | Attention Deficit Disorder With Hyperactivity | - | - |
OROS hydromorphone HCl | Phase 3 | Pain | - | - |
Peginterferon-alpha (PegIFNα-2a) | Phase 3 | Hepatitis C, Chronic | - | - |
Decitabine 20 mg/m^2 | Phase 3 | Leukemia, Myeloid, Acute | - | - |
MVA-BN-Filo | Phase 3 | Hemorrhagic Fever, Ebola | - | - |
Genetic: AAV5-hRKp.RPGR Intermediate Dose | Phase 3 | X-Linked Retinitis Pigmentosa | - | - |
Ad26.Mos4.HIV | Phase 3 | Healthy | - | - |
Icotrokinra | Phase 3 | Crohn Disease | - | - |
Remifentanil | Phase 3 | Anesthesia | - | - |
Pegylated interferon alfa-2a | Phase 3 | Chronic Hepatitis C Virus (HCV) Infection | - | - |
Sirukumab 50 mg | Phase 3 | Depressive Disorder, Major | - | - |
Guselkumab dose 1 | Phase 3 | Hidradenitis Suppurativa | - | - |
Aticaprant | Phase 3 | Depressive Disorder, Major | - | - |
Milvexian | Phase 3 | Acute Coronary Syndrome | - | - |
Fentanyl 1-day transdermal patch (Titration Phase) | Phase 3 | Pain | - | - |
ER OROS paliperidone | Phase 3 | Schizophrenia | - | - |
Efgartigimod | Phase 3 | Myasthenia Gravis | - | - |
Erdafitinib | Phase 3 | Advanced Solid Tumor | - | - |
rivaroxaban 15 mg | Phase 3 | Atrial Fibrillation | - | - |
Group 2 ustekinumab 130 mg | Phase 3 | Crohn's Disease | - | - |
5-Flurouracil | Phase 3 | Squamous Cell Carcinoma of Head and Neck | - | - |
CNTO 1959 50 mg | Phase 3 | Psoriasis | - | - |
ExPEC9V | Phase 3 | Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention | - | - |
NUCYNTA | Phase 3 | Pain | - | - |
Paliperidone palmitate (R092670) | Phase 3 | Schizophrenia | - | - |
paliperidone palmitate injection | Phase 3 | Schizophrenia | - | - |
TAR-210 | Phase 3 | Non-Muscle Invasive Bladder Neoplasms | - | - |
Vinflunine | Phase 3 | Urothelial Cancer | - | - |
Guselkumab Dose 2 | Phase 3 | Colitis, Ulcerative | - | - |
PP3M 175 mg eq. | Phase 3 | Schizophrenia | - | - |
Ustekinumab IV | Phase 3 | Colitis, Ulcerative | - | - |
DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC | Phase 3 | HIV-1 | - | - |
Canagliflozin 100 mg | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Ad26.ZEBOV | Phase 3 | Ebola Virus Disease | - | - |
Bendamustine hydrochloride | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
R331333 (referred to as JNS024 ER or CG5503) | Phase 3 | Pain | - | - |
Genetic: AAV5-hRKp.RPGR | Phase 3 | X-Linked Retinitis Pigmentosa | - | - |
Efavirenz | Phase 3 | Human Immunodeficiency Virus-type 1 Infection | - | - |
Pegylated interferon alfa-2a (PegIFNα-2a) | Phase 3 | Hepatitis C, Chronic | - | - |
Golimumab | Phase 3 | Arthritis, Juvenile | - | - |
Guselkumab 100 mg | Phase 3 | Psoriasis | - | - |
Risankizumab | Phase 3 | Crohn Disease | - | - |
Nipocalimab | Phase 3 | Arthritis, Rheumatoid | - | - |
Telaprevir | Phase 3 | Hepatitis C, Chronic | - | - |
Pegylated interferon alpha-2a | Phase 3 | Hepatitis C Virus Genotype-1 | - | - |
ustekinumab 45 mg | Phase 3 | Arthritis, Psoriatic | - | - |
Durogesic® (fentanyl transdermal drug delivery system) | Phase 3 | Chronic Pain | - | - |
Paliperidone ER OROS® | Phase 3 | Schizophrenia | - | - |
Canagliflozin | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Abiraterone acetate | Phase 3 | Prostate Neoplasms | - | - |
Ad26.ZEBOV 5*10^10 viral particles (vp) | Phase 3 | Healthy | - | - |
Intravenous immunoglobulins (IVIG) | Phase 3 | Thrombocytopenia, Neonatal Alloimmune | - | - |
methylphenidate | Phase 3 | Depressive Disorder, Major | - | - |
Sirukumab | Phase 3 | Arthritis, Rheumatoid | - | - |
Daratumumab IV | Phase 3 | Multiple Myeloma | - | - |
Paliperidone extended release (ER) | Phase 3 | Schizophrenia | - | - |
Ad26.RSV.PreF-based Vaccine | Phase 3 | Respiratory Syncytial Virus Prevention | - | - |
Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF | Phase 3 | Respiratory Syncytial Viruses | - | - |
D/C/F/TAF | Phase 3 | Human Immunodeficiency Virus Type 1 | - | - |
Nesiritide | Phase 3 | Heart Decompensation | - | - |
Fumaric Acid Esters | Phase 3 | Psoriasis | - | - |
Temsirolimus | Phase 3 | Mantle Cell Lymphoma | - | - |
Sofosbuvir | Phase 3 | Chronic Hepatitis C | - | - |
Epo-alpha | Phase 3 | Resuscitation | - | - |
Tapentadol (CG5503) Extended Release (ER) | Phase 3 | Pain | - | - |
Rivaroxaban (Xarelto, BAY59-7939) | Phase 3 | Venous Thromboembolism | - | - |
Morphine | Phase 3 | Hysterectomy | - | - |
oxycodone | Phase 3 | Osteoarthritis, Knee | - | - |
Risperidone, long-acting injectable | Phase 3 | Schizophrenia | - | - |
risperidone; quetiapine | Phase 3 | Bipolar Disorder | - | - |
topiramate, propranolol | Phase 3 | Migraine | - | - |
Enoxaparin | Phase 3 | Venous Thromboembolism | - | - |
CG5503 IR | Phase 3 | Bunionectomy | - | - |
Acetaminophen | Phase 3 | Post Operative Analgesia | - | - |
oxycodone CR | Phase 3 | Joint Diseases | - | - |
tramadol, acetaminophen | Phase 3 | Diabetic Neuropathies | - | - |
risperidone oral tablets | Phase 3 | Anxiety Disorders | - | - |
Risperidone long-acting injectable | Phase 3 | Schizophrenia | - | - |
Tapentadol ER (100 to 250 mg twice daily) | Phase 3 | Pain | - | - |
Cyclophosphamide 750 mg/m^2 | Phase 3 | Mantle Cell Lymphoma | - | - |
recombinant human erythropoietin alfa | Phase 3 | Infarction, Middle Cerebral Artery | - | - |
Micronized 17B-estradiol | Phase 3 | Atherosclerosis | - | - |
levofloxacin; amoxicillin/clavulanate | Phase 3 | Otitis Media | - | - |
VELCADE Administered by subcutaneous injection | Phase 3 | Multiple Myeloma | - | - |
Risperidone, oral tablets | Phase 3 | Bipolar Disorders | - | - |
levofloxacin, azithromycin, amoxicillin/clavulanate | Phase 3 | Bronchitis | - | - |
Conventional Antiarrhythmic Drug Therapy | Phase 3 | Atrial Fibrillation | - | - |
Test acetaminophen | Phase 3 | Post-operative Dental Pain | - | Patent 2032 |
CG 5503;tapentadol | Phase 3 | Osteoarthritis | - | - |
tapentadol (CG5503) ER | Phase 3 | Low Back Pain | - | - |
levofloxacin | Phase 3 | Pneumonia | - | |
Rivaroxaban | Phase 3 | Atrial Fibrillation | - | Patent 2034 |
tapentadol (CG5503) Immediate Release IR | Phase 3 | Low Back Pain | - | - |
Acetaminophen/Naproxen Sodium Fixed Combination | Phase 3 | Pain | - | - |
Paliperidone extended-release | Phase 3 | Bipolar Disorder | - | - |
Risperdal Consta | Phase 3 | Bipolar Disorder | - | - |
Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD) | Phase 3 | Multiple Myeloma | - | - |
paliperidone ER Oros | Phase 3 | Schizophrenia | - | |
Gemcitabine with R115777 | Phase 3 | Pancreatic Neoplasms | - | - |
Mebendazole | Phase 3 | Healthy Volunteers | - | |
Dapoxetine | Phase 3 | Erectile Dysfunction | - | - |
F# 13418-148 Eye Drops | Phase 3 | Ophthalmic Solutions | - | - |
Rivaroxaban 2.5 mg | Phase 3 | Acute Coronary Syndrome | - | Patent 2034 |
Paliperidone ER | Phase 3 | Schizophrenia | - | |
topiramate | Phase 3 | Essential Tremor | - | Patent 2040 |
doripenem | Phase 3 | Pneumonia | - | |
norelgestromin + ethinyl estradiol | Phase 3 | Contraception | - | - |
Rabeprazole sodium 5 mg | Phase 3 | Gastroesophageal Reflux | - | |
Tapentadol extended release (ER) | Phase 3 | Diabetic Peripheral Neuropathy | - | - |
Thalidomide | Phase 3 | Multiple Myeloma | - | - |
CG5503 IR;tapentadol | Phase 3 | Arthralgia | - | - |
Topiramate; Carbamazepine; Valproate | Phase 3 | Epilepsy | - | - |
levofloxacin; imipenem/cilastitin | Phase 3 | Nosocomial Pneumonia | - | - |
Pancrease MT 10.5, or MT 21 | Phase 3 | Exocrine Pancreatic Insufficiency | - | - |
Colloidal Oatmeal Cream | Phase 3 | Eczema | - | - |
ivermectin | Phase 3 | Lice Infestations | - | - |
Paliperidone palmitate 25 mg eq. | Phase 3 | Schizophrenia | - | - |
JNJ-90301900 (NBTXR3) | Phase 3 | Locally Advanced Head and Neck Squamous Cell Carcinoma | - | - |
norelgestromin + ethinyl estradiol; mercilon | Phase 3 | Contraception | - | - |
Extended-release galantamine hydrobromide | Phase 3 | Schizophrenia | - | - |
Test naproxen sodium tablet | Phase 3 | Post-operative Dental Pain | - | - |
galantamine | Phase 3 | Alzheimer's Disease | - | - |
5% Minoxidil Topical Foam | Phase 3 | Androgenetic Alopecia | - | - |
Imonogas | Phase 3 | Functional Dyspepsia | - | - |
rabeprazole | Phase 3 | Gastroesophageal Reflux Disease (GERD) | - | - |
galantamine hydrobromide | Phase 3 | Alzheimer Disease | - | - |
Hydromorphone HCl | Phase 3 | Pain | - | - |
topiramate, phenytoin | Phase 3 | Epilepsy | - | - |
Paliperidone palmitate | Phase 3 | Schizophrenia | - | - |
norelgestromin + ethinyl estradiol; triphasil. | Phase 3 | Contraception | - | - |
doripenum | Phase 3 | Urinary Tract Infections | - | - |
acetaminophen extended release | Phase 3 | Osteoarthritis | - | - |
CG5503 | Phase 3 | Diabetic Neuropathy | - | - |
Duragesic® (fentanyl) Therapeutic Transdermal System (TTS) | Phase 3 | Chronic Pain | - | - |
CG5503 IR; tapentadol | Phase 3 | Osteoarthritis | - | - |
5% Minoxidil | Phase 3 | Alopecia | - | - |
naproxen | Phase 3 | Osteoarthritis, Hip | - | - |
minoxidil | Phase 3 | Androgenetic Alopecia | - | - |
PDE5I (phosphodiesterase-5 inhibitor) | Phase 3 | Erectile Dysfunction | - | - |
Extended Release OROS® Paliperidone | Phase 3 | Schizophrenia | - | - |
acetaminophen Tablet | Phase 3 | Post Operative Dental Pain | - | - |
Paliperidone | Phase 3 | Schizophrenia | - | - |
Tipifarnib;Zarnestra; R115777 | Phase 3 | Acute Myeloid Leukemia | - | - |
Epoetin alfa 3 times weekly /once weekly | Phase 3 | Anemia | - | - |
epoetin alfa | Phase 3 | Chronic Kidney Disease | - | - |
Prucalopride | Phase 3 | Constipation | - | - |
Tapentadol Extended Release | Phase 3 | Tumor | - | - |
Ibrutinib | Phase 3 | Leukemia, Lymphocytic, Chronic, B-Cell | - | - |
TAR-200 | Phase 3 | Non-Muscle Invasive Bladder Neoplasms | - | - |
Levetiracetam | Phase 3 | Epilepsy | - | - |
Cilta-cel | Phase 3 | Multiple Myeloma | - | - |
Talquetamab | Phase 3 | Multiple Myeloma | - | - |
TMC435 | Phase 3 | Hepatitis C | - | - |
JNJ-77242113 | Phase 3 | Plaque Psoriasis | - | - |
Simeprevir | Phase 3 | Hepatitis C Virus Infection | - | - |
Fentanyl | Phase 3 | Postherpetic Neuralgia | - | - |
No treatment | Phase 3 | Hepatitis C | - | - |
JNJ-63723283 | Phase 3 | Multiple Myeloma | - | - |
Guselkumab | Phase 3 | Psoriasis | - | - |
Daratumumab | Phase 3 | Multiple Myeloma | - | - |
Fulranumab 1 mg | Phase 3 | Osteoarthritis | - | - |
Ad26.COV2.S | Phase 3 | Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol | - | - |
Macitentan | Phase 3 | Pulmonary Arterial Hypertension | - | - |
Rilpivirine | Phase 3 | HIV-1 | - | - |
Amivantamab | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Sirukumab 100 mg | Phase 3 | Arthritis, Rheumatoid | - | - |
Seltorexant | Phase 3 | Depressive Disorder, Major | - | - |
Ustekinumab | Phase 3 | Crohn Disease | - | - |
Teclistamab | Phase 3 | Multiple Myeloma | - | - |
Ustekinumab 90 mg SC q8w | Phase 3 | Crohn's Disease | - | - |
Group 1: Epoetin alfa | Phase 3 | Myelodysplastic Syndromes | - | - |
Lazertinib | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
PP6M | Phase 3 | Schizophrenia | - | - |
Etravirine | Phase 3 | HIV Infections | - | - |
Tapentadol (CG5503) | Phase 3 | Arthralgia | - | - |
R228060 | Phase 2 | Major Depressive Disorder | - | - |
Daratumumab 16 mg/kg (Part 1) | Phase 2 | Multiple Myeloma | - | - |
Capmatinib | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
JNJ-40411813 | Phase 2 | Major Depressive Disorder | - | - |
JNJ-90301900 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Experimental Product 1% Colloidal Oatmeal Balm | Phase 2 | Atopic Dermatitis | - | - |
VELCADE (bortezomib) | Phase 2 | Multiple Myeloma | - | - |
JNJ16269110 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
JNJ-40346527 | Phase 2 | Arthritis, Rheumatoid | - | - |
ibuprofen; pseudoephedrine HCl | Phase 2 | Enuresis | - | - |
JNJ-64304500 | Phase 2 | Crohn Disease | - | - |
Abiraterone | Phase 2 | Prostate Cancer | - | - |
NNC 0142-0000-0002 | Phase 2 | Inflammation | - | - |
Cetrelimab | Phase 2 | Urinary Bladder Neoplasms | - | - |
Canagliflozin 50 mg | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Amivantamab IV | Phase 2 | Advanced or Metastatic Colorectal Cancer | - | - |
Glucocorticoids | Phase 2 | Myositis | - | - |
tapentadol HCl | Phase 2 | Pain | - | - |
JNJ-73763989 | Phase 2 | Hepatitis B, Chronic | - | - |
JNJ-39393406 | Phase 2 | Depression | - | - |
JNJ-37822681 | Phase 2 | Schizophrenia | - | - |
CNTO 2476 3.0 x 10^5 cells | Phase 2 | Visual Acuity | - | - |
Alimta | Phase 2 | Non-Small Cell Lung Cancer | - | - |
NNC0142-0002 | Phase 2 | Inflammation | - | - |
RSV Vaccine | Phase 2 | Healthy | - | - |
R092670 | Phase 2 | Schizophrenia | - | - |
Ad26.ZEBOV vaccine | Phase 2 | Ebola Virus Disease | - | - |
VELCADE | Phase 2 | Diffuse Large B-Cell Lymphoma | - | - |
Tapentadol | Phase 2 | Pain | - | - |
JNJ-41443532 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Lymphodepleting Therapy (Cyclophosphamide and Fludarabine) | Phase 2 | Multiple Myeloma | - | - |
JNJ-39588146 5 ng/kg/min | Phase 2 | Heart Failure | - | - |
tipifarnib (R115777) | Phase 2 | Leukemia, Nonlymphocytic, Acute | - | - |
JNJ39758979 | Phase 2 | Asthma | - | - |
cholecalciferol | Phase 2 | Prostate Cancer | - | - |
Nesiritide (1+0.01) | Phase 2 | Heart Failure, Congestive | - | - |
R115777 | Phase 2 | Glioblastoma Multiforme | - | - |
Imipenem/cilastatin | Phase 2 | Pneumonia, Ventilator-Associated | - | - |
JNJ-31001074 | Phase 2 | Attention Deficit Hyperactivity Disorder | - | - |
MVA-Mosaic | Phase 2 | Human Immunodeficiency Virus | - | - |
Apalutamide | Phase 2 | Salivary Gland Neoplasms | - | - |
VX-787 300 mg | Phase 2 | Influenza A | - | - |
JNJ 40929837 | Phase 2 | Asthma | - | - |
JNJ-53718678 | Phase 2 | Respiratory Syncytial Virus Infections | - | - |
R209130 | Phase 2 | Schizophrenia | - | - |
Daratumumab Injection | Phase 2 | Plasma Cell Disorder | - | - |
JNJ-42165279 | Phase 2 | Depressive Disorder | - | - |
Olomorasib | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
R256918 | Phase 2 | Obesity | - | - |
Ad26.RSV.preF | Phase 2 | Respiratory Syncytial Virus | - | - |
ZARNESTRA, tipifarnib, R115777 | Phase 2 | Acute Myeloid Leukemia | - | - |
Siltuximab | Phase 2 | Multicentric Castleman's Disease | - | - |
Antipsychotic medication | Phase 2 | Schizophrenia | - | - |
JNJ-17166864 | Phase 2 | Allergic Rhinitis | - | - |
Acetaminophen (ACE) (1000 mg) | Phase 2 | Dental Pain | - | - |
T2-18C3 therapeutic antibody | Phase 2 | Type 2 Diabetes | - | - |
Ad26.Mos.HIV | Phase 2 | Healthy | - | - |
bortezomib, dexamethasone, and thalidomide | Phase 2 | Multiple Myeloma | - | - |
JNJ-81201887 | Phase 2 | Geographic Atrophy | - | - |
Oral Dexamethasone | Phase 2 | Multiple Myeloma | - | - |
PROCRIT (Epoetin alfa) | Phase 2 | Anemia | - | - |
Erdafitinib Intravesical Delivery System | Phase 2 | Non-Muscle Invasive Bladder Neoplasms | - | - |
JNJ-42847922 | Phase 2 | Depressive Disorder, Major | - | - |
Acetaminophen/naproxen sodium Dose A | Phase 2 | Pain | - | - |
Standard-of-care treatment | Phase 2 | Systemic Lupus Erythematosus | - | - |
Atazanavir (ATV) 300 mg | Phase 2 | HIV Infections | - | - |
Blink® Tears eye drops in a multidose bottle | Phase 2 | Visual Acuity | - | - |
Ad26.RSV.preF (1*10^11 vp) | Phase 2 | Respiratory Syncytial Viruses | - | - |
ExPEC4V (4 : 4 : 4 : 4) | Phase 2 | Healthy | - | - |
TMC207 (bedaquiline) | Phase 2 | Tuberculosis, Multidrug-Resistant | - | - |
440 mg naproxen sodium with 1000 mg acetaminophen | Phase 2 | Pain | - | - |
JNJ-26489112 | Phase 2 | Photosensitive Epilepsy | - | - |
Atomoxetine 80 mg/d | Phase 2 | Attention Deficit Hyperactivity Disorder | - | - |
ET743 | Phase 2 | Breast Neoplasms | - | - |
Investigational Lubricating Eye Drop in a Novelia® bottle | Phase 2 | Dry Eye | - | - |
JNJ-39220675 | Phase 2 | Allergic Rhinitis | - | - |
Escitalopram | Phase 2 | Major Depressive Disorder | - | - |
Yondelis | Phase 2 | Liposarcoma | - | - |
sIPV | Phase 2 | Healthy | - | - |
JNJ-63623872 | Phase 2 | Influenza A Virus | - | - |
CNTO 1959 | Phase 2 | Palmoplantaris Pustulosis | - | - |
AL-335 | Phase 2 | Hepatitis C, Chronic | - | - |
JNJ 49095397 | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
JNJ-64565111 Dose Level 1 | Phase 2 | Obesity and Diabetes Mellitus, Type 2 | - | - |
Ketoconazole | Phase 2 | Neoplasm Metastases | - | - |
Canagliflozin (JNJ-28431754) | Phase 2 | Diabetes Mellitus, Type II | - | - |
RWJ-445380 100 mg | Phase 2 | Rheumatoid Arthritis | - | - |
Fluarix | Phase 2 | Healthy | - | - |
Schizophrenia
4 drugs in this indication
Bipolar Disorder
3 drugs in this indication
Pain
2 drugs in this indication
Multiple Myeloma
2 drugs in this indication
Pneumonia
2 drugs in this indication
Diabetes Mellitus, Type 2
2 drugs in this indication
Low Back Pain
2 drugs in this indication
relapsed or refractory multiple myeloma
2 drugs in this indication
Pain relief
2 drugs in this indication
relapsed/refractory multiple myeloma
2 drugs in this indication
Major Depressive Disorder
1 drug in this indication
Ophthalmic Solutions
1 drug in this indication
Acute Coronary Syndrome
1 drug in this indication
Contraception
1 drug in this indication
Post-operative Dental Pain
1 drug in this indication
Chronic Kidney Disease
1 drug in this indication
Healthy Volunteers
1 drug in this indication
Osteoarthritis
1 drug in this indication
Erectile Dysfunction
1 drug in this indication
Atrial Fibrillation
1 drug in this indication
Alzheimer's Disease
1 drug in this indication
Carcinoma, Non-Small-Cell Lung
1 drug in this indication
Enuresis
1 drug in this indication
Pancreatic Neoplasms
1 drug in this indication
Gastroesophageal Reflux
1 drug in this indication
Atopic Dermatitis
1 drug in this indication
Essential Tremor
1 drug in this indication
recurrent or metastatic head and neck cancer
1 drug in this indication
Sprains and Strains
1 drug in this indication
Diabetic Peripheral Neuropathy
1 drug in this indication
Heart Failure
1 drug in this indication
SLE (Systemic Lupus Erythematosus)
1 drug in this indication
depression
1 drug in this indication
Leukemia, Nonlymphocytic, Acute
1 drug in this indication
relapsed/refractory multiple myeloma after at least one prior therapy
1 drug in this indication
over-the-counter treatment of pain
1 drug in this indication
Asthma
1 drug in this indication
axial psoriatic arthritis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Johnson & Johnson's drug pipeline?→
CatalystAlert tracks 265 drug candidates in Johnson & Johnson's (JNJ) pipeline across Phase 3, Phase 2. Its lead program is galantamine ER (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Johnson & Johnson's next FDA catalyst?→
Johnson & Johnson's (JNJ) next tracked catalyst is a Earnings expected October 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track JNJ biotech catalysts?→
Add JNJ to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Johnson & Johnson's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.